

2024 OPA Annual Conference Learning Objectives

ACPE #0129-0000-24-015-L99-P **0.1 CEU** **Note: Live Only**

Coping with COEPA: A Preceptor's Guide to Measuring a Student's Practice Readiness

Brenda Pahl, PharmD, BCPS and Zach Jenkins, PharmD, BCPS

At the completion of this activity, the participant will be able to:

1. describe the 2022 AACP Curriculum Outcomes and Entrustable Professional Activities (COEPA) standards;
2. explain the alignment of the Pharmacist Patient Care Process with COEPA; and
3. select a learning activity that highlights a student's "practice readiness."

ACPE #0129-0000-24-016-L04-P **0.1 CEU**

ACPE #0129-0000-24-016-H04-P **0.1 CEU**

A Contract Pharmacy's Guide to Navigating 340B Manufacturer Restrictions

Jason Martinez, PharmD, BCACP

At the completion of this activity, the participant will be able to:

1. review the current landscape regarding restrictions on 340B pricing under contract pharmacy arrangements and limited exceptions;
2. describe strategies covered entities use to reduce the negative impact of manufacturers' restrictions on contract pharmacy; and
3. review the process for designation of contract pharmacies.

ACPE #0129-0000-24-017-L01-P **0.1 CEU**

ACPE #0129-0000-24-017-H01-P **0.1 CEU**

The Implications of Chemical Dependency in the Profession of Pharmacy in Ohio and the Role of PRO, Inc.

Andy Pierron, BSP Pharm, R.Ph.

At the completion of this activity, the participant will be able to:

1. recall the definition of impaired licensees and registrants under the Ohio Administrative Code;
2. explain the implications of duty to report as a healthcare provider in the profession of pharmacy; and
3. describe monitoring programs, PRO, and how PRO supports impaired licensees and registrants suffering from substance use disorder.

ACPE #0129-0000-24-018-L01-P **0.1 CEU**

ACPE #0129-0000-24-018-H01-P **0.1 CEU**

Contraceptive Options for Patients with Risk or History of Thrombosis

Leah Fagan, PharmD

At the completion of this activity, the participant will be able to:

1. explain risk of combined oral contraception in patients with risk or history of thrombosis;
2. recall options for contraception for patients with risk of thrombosis;
3. examine options for contraception for patients with history of thrombosis currently on anticoagulation; and
4. discuss upcoming OTC contraception options for patients and their risk of thrombosis.

ACPE #0129-0000-24-019-L01-P **0.15 CEU**

ACPE #0129-0000-24-019-H01-P **0.15 CEU**

Cardiovascular-Kidney-Metabolic Health: Patient Risk Assessment and Health Equity

Maria (Pruchnicki) Coyle, PharmD, FCCP, BCPS, BCACP, CLS

At the completion of this activity, the participant will be able to:

1. define cardiovascular-kidney-metabolic (CKM) syndrome according to the 2023 American Heart Association (AHA) Scientific Statement, including key goals for the novel framework;
2. summarize recent and developing updates for risk estimation equations commonly used in clinical practice, particularly sex-specific, race-free equations for estimating kidney function and the PREVENT equations for total cardiovascular disease (CVD) risk;

3. describe nontraditional factors that may enhance predictive usefulness of CVD risk assessment tools in the future;
4. demonstrate how the CKM model could include social determinants of health to improve health equity and benefit minority populations; and
5. discuss clinical implementation, risk communication, and education strategies that will facilitate future adoption of the CKM prevention model in various practice settings.

ACPE #0129-0000-24-020-L01-P **0.15 CEU** **Note: Live Only**

2024 OTC and Self-Care Challenge

Moderators: Max Conrad, PharmD, MS and Mickie Gray, PharmD

At the completion of this activity, the participant will be able to:

1. identify and explain aspects of the effective and safe practice of pharmacy self-care treatments;
2. describe at least two over-the-counter and prescription medication interactions that pharmacists should be aware of;
3. list three OTC medications and their use; and
4. identify counseling points for each of three OTC medications.

ACPE #0129-0000-24-021-L04-P **0.15 CEU**

ACPE #0129-0000-24-021-H04-P **0.15 CEU**

Ohio Innovative Practice Forum 2024

Moderators: Jennifer Rodis, PharmD, FAPhA, and Aleda Chen, PharmD, PhD, FAPhA

At the completion of this activity, the participant will be able to:

1. describe innovative pharmacy practice models in Ohio;
2. explain how individual pharmacy practices and practitioners are expanding patient care services;
3. describe the successes and challenges of these programs including their financial viability and impact on outcome measures; and
4. apply these ideas, opportunities, and resources to enhance their own pharmacy practice.

ACPE #0129-0000-24-022-L07-P **0.15 CEU**

ACPE #0129-0000-24-022-H07-P **0.15 CEU**

What You Must Know About Women's Hormones: The Science

Pamela W. Smith, M.D., MPH, MS, Personalized Medicine Physician and Author

At the completion of this activity, the participant will be able to:

1. identify the symptoms of peri-menopause and menopause;
2. describe the biochemistry and physiology of female hormones;
3. describe the functions of hormones such as estrogen, progesterone, DHEA, and pregnenolone ;
4. explain the science behind bio-identical hormone replacement; and
5. describe considerations for selecting compounded hormone replacement products.

ACPE #0129-0000-24-023-L99-P **0.1 CEU**

ACPE #0129-0000-24-023-H99-P **0.1 CEU**

Ohio Research Forum 2024

Moderator: Aleda Chen, PharmD, PhD, FAPhA

At the completion of this activity, the participant will be able to:

1. describe research projects being conducted by pharmacists, student pharmacists and faculty in Ohio; and
2. describe the impact these research projects have on the practice of pharmacy, economic/social/administrative areas within the profession and/or pharmacy education.

ACPE #0129-0000-24-024-L99-P **0.1 CEU**

ACPE #0129-0000-24-024-H99-P **0.1 CEU**

Beyond the Counter: OPA's Public Health Initiatives

Moderator: Myriam Shaw Ojeda, R.Ph., PharmD

At the completion of this activity, the participant will be able to:

1. outline the best practices for managing nicotine use disorders using Ohio's NRT dispensing rules;
2. describe the status of lead-related health concerns in light of the pharmacist's role;
3. define ways that Pharmacists can communicate effectively with rural populations amid misinformation.

ACPE #0129-0000-24-025-L01-P **0.1 CEU**

ACPE #0129-0000-24-025-H01-P **0.1 CEU**

Overview of the Treatment of Post Traumatic Stress Disorder

Christopher Thomas, PharmD, BCPP, BCPS

At the completion of this activity, the participant will be able to:

1. recognize the commonality and proposed pathophysiology of the Trauma and Stress-Related Disorders;
2. describe the symptom clusters that are required for a patient to meet diagnostic criteria of Trauma and Stress-Related Disorders;
3. examine the current literature regarding medications used to treat PTSD; and
4. apply the PTSD literature and Veterans Affairs/Department of Defense (VA/DoD) Guidelines to determine which medication option is most appropriate in treating a specific symptom in a patient with PTSD.

ACPE #0129-0000-24-026-L03-P **0.1 CEU**

ACPE #0129-0000-24-026-H03-P **0.1 CEU**

Brain-teaser Questions and Cases in Pharmacy Practice Law

Donnie Sullivan, R.Ph., PhD

At the completion of this activity, the participant will be able to:

1. interpret patient care situations related to pharmacy practice laws and rules;
2. interpret cases related to dispensing and recordkeeping; and
3. interpret cases related to new pharmacy practice laws.

ACPE #0129-0000-24-027-L01-P **0.1 CEU**

ACPE #0129-0000-24-027-H01-P **0.1 CEU**

Navigating Weight Management: Exploring Root Cause Pathophysiology and Holistic Strategies

Melody L. Hartzler, PharmD, BCACP, BC-ADM

At the completion of this activity, the participant will be able to:

1. explain the root cause pathophysiology driving weight loss resistance and obesity;
2. identify nutrition strategies beyond caloric restriction; and
3. discuss integrative and functional medicine approaches to a holistic weight management plan.

ACPE #0129-0000-24-028-L01-P **0.1 CEU**

ACPE #0129-0000-24-028-H01-P **0.1 CEU**

Recreational Marijuana in Ohio: What to Know in 2024

Christopher Hernandez, PharmD, BCACP

At the completion of this activity, the participant will be able to:

1. compare and contrast different formulations of marijuana;
2. discuss necessary medication adjustments needed with concomitant use of marijuana; and
3. identify signs and symptoms of marijuana misuse and overuse.

SATURDAY

ACPE #0129-0000-24-029-L01-P 0.1 CEU

ACPE #0129-0000-24-029-H01-P 0.1 CEU

Deprescribing: An Approach to Optimize Medications

Courtney Myers, PharmD, BCGP

At the completion of this activity, the participant will be able to:

1. identify individuals potentially appropriate for deprescribing;
2. review medications to prioritize for deprescribing utilizing a patient-centered approach; and
3. describe and apply a strategy for safe medication reduction and/or discontinuation.

ACPE #0129-0000-24-030-L05-P 0.1 CEU

ACPE #0129-0000-24-030-H05-P 0.1 CEU

It's Raining Cats and Dogs: Preventing Veterinary Medication Errors

Lauren Forsythe, PharmD, DICVP

At the completion of this activity, the participant will be able to:

1. summarize common errors that occur when filling veterinary prescriptions;
2. examine underlying causes of errors associated with veterinary prescriptions; and
3. employ communication strategies to bridge the gap between veterinarians and pharmacists.

ACPE #0129-0000-24-031-L99-P 0.1 CEU

ACPE #0129-0000-24-031-H99-P 0.1 CEU

Right Here, Right Now: Managing Stress and Anxiety in the Moment

Cynthia Knapp Dlugosz, BSPHarm, NBC-HWC

At the completion of this activity, the participant will be able to:

1. discuss the neurobiology of acute and chronic stress and anxiety;
2. recognize how our prehistoric survival brain works against us in the modern world;
3. demonstrate brief, evidence-based approaches to managing the physical manifestations of the stress response; and
4. demonstrate brief, evidence-based approaches to addressing the cognitive and emotional aspects of stress.

ACPE #0129-0000-24-032-L99-P 0.15 CEU

ACPE #0129-0000-24-032-H99-P 0.15 CEU

2024 Legislative Update

Michelle Fitzgibbon; David Burke, R.Ph., MBA; and E. Michael Murphy, PharmD, MBA

At the completion of this activity, the participant will be able to:

1. discuss current legislative and policy changes at both the state and federal level that will impact the practice of pharmacy;
2. explain how to effectively advocate for OPA supported legislative changes with state legislators and federal elected officials; and
3. identify issues on OPA's legislative agenda for 2023-24 and what they may mean for pharmacy practice.

ACPE #0129-0000-24-033-L06-P 0.15 CEU

ACPE #0129-0000-24-033-H06-P 0.15 CEU

Immunizations Update 2024

Rebecca Lahrman, PharmD, R.Ph., MS, BCACP and Andrea Kowalski, PharmD, R.Ph.

At the completion of this activity, the participant will be able to:

1. describe Advisory Committee on Immunization Practices (ACIP) updates, including new vaccine opportunities such as respiratory syncytial virus;
2. identify best practices in using ImpactSIS and other tools for clinical decision making; and
3. review travel vaccine recommendations and patient education to support patient centered goals.

ACPE #0129-0000-24-034-L01-P 0.15 CEU

ACPE #0129-0000-24-034-H01-P 0.15 CEU

Using DNA-targeted Precision Medicine in a Clinical Pharmacy Role Using a Genomic Clinical Decision Support Tool

Dr. Laura Lile, M.D., R.Ph.

At the completion of this activity, the participant will be able to:

1. explain the broad application of genomics as a prevention and intervention strategy;
2. illustrate the importance of pharmacists in genomics; and
3. recognize how pharmacists can consult with complex patients through genomic testing

ACPE #0129-0000-24-035-L04-P 0.15 CEU **Note: Live Only**

Innovative Pharmacy Business Plan Competition 2024

Finalist teams TBD

At the completion of this activity, the participant will be able to:

1. identify essential components of a business plan, including mission statement, description of business, loan request, marketing plan and financial reports;
2. explain the importance of effective visual aids and nonverbal communication during presentation of a business plan; and
3. recognize how enthusiasm, professionalism and completeness can impact the effectiveness of a business plan presentation.

ACPE #0129-0000-24-036-L03-P 0.1 CEU

ACPE #0129-0000-24-036-H03-P 0.1 CEU

2024 Ohio Law Review

Katie Stabi, PharmD, BCPS, R.Ph.

At the completion of this activity, the participant will be able to:

1. identify recent changes in state and federal laws and rules which impact pharmacy practice in Ohio;
2. describe the effect of recent law and rule changes on the practice of pharmacy;
3. discuss implementation strategies for law and rule compliance; and
4. review relevant board notices and publications.

ACPE #0129-0000-24-037-L99-P 0.1 CEU

ACPE #0129-0000-24-037-H99-P 0.1 CEU

Digital Health: Past, Present and Future

Michael Dorsch, PharmD, MS, FCCP, FAHA, FACC

At the completion of this activity, the participant will be able to:

1. describe digital health;
2. explain the regulatory landscape for digital health;
3. identify how a smartphone app or wearable can be used to help patients; and
4. summarize the potential pitfalls of digital health.

ACPE #0129-0000-24-038-L01-P 0.1 CEU

ACPE #0129-0000-24-038-H01-P 0.1 CEU

Implementation of Pharmacists in Outpatient Specialist Care: Cardio-Renal-Metabolic Involvement

Ebne Rafi, PharmD, BCACP; Brayden Dunn, PharmD, BCPS; Matthew Nennstiel, PharmD

At the completion of this activity, the participant will be able to:

1. explain the cardiac and potential renal benefits of GLP1ra agents;
2. list the cardiac and renal benefits of SGLT2i agents; and
3. recognize different workflow models where pharmacists can be involved in outpatient care.

ACPE #0129-0000-24-039-L04-P 0.1 CEU

ACPE #0129-0000-24-039-H04-P 0.1 CEU

Entrepreneurship in Pharmacy Practice

Scott G. Hughes, R.Ph.; Nick Newman, PharmD; Kimber Boothe, PharmD, MHA

At the completion of this activity, the participant will be able to:

1. illustrate steps taken to open an independent pharmacy and lessons learned;
2. compare alternative paths within the profession of pharmacy; and
3. understand management consulting as a business model from start to scale.

ACPE #0129-0000-24-048-L99-P 0.1 CEU

ACPE #0129-0000-24-048-H99-P 0.1 CEU

Artificial Intelligence in Community Pharmacy Practice

Olivia Kinney, PharmD, MS

At the completion of this activity, the participant will be able to:

1. define artificial intelligence and its origin;
2. identify best practices for responsible use of artificial intelligence;
3. discuss barriers to artificial intelligence implementation in pharmacy practice; and
4. discuss use cases for artificial intelligence in pharmacy practice.

ACPE #0129-0000-24-040-L01-P 0.1 CEU **Note: Live Only**

The Future is Clear: Treatment Options for Atopic Dermatitis and the Role of Specialty Pharmacy in Dermatology

Alexis Mod, PharmD

At the completion of this activity, the participant will be able to:

1. discuss the background and disease burden of atopic dermatitis;
2. review the American Academy of Dermatology 2023 guidelines for the treatment of atopic dermatitis and apply these guidelines to a patient case;
3. evaluate the efficacy and safety study outcomes of recently approved therapies and provide key counseling points; and
4. describe the role of specialty pharmacy and specialty pharmacist in the outpatient dermatology setting.

ACPE #0129-0000-24-041-L01-P 0.1 CEU

ACPE #0129-0000-24-041-H01-P 0.1 CEU

Are You Ready For It? Insights Into Progressive Diabetes Management

Marilee Clemons, PharmD, BCACP; Sarah Aldrich Renner, PharmD, BCACP

At the completion of this activity, the participant will be able to:

1. discuss diabetes management updates for pharmacists;
2. summarize pharmacotherapeutic and nonpharmacotherapeutic approaches for management of diabetes; and
3. select an appropriate patient specific treatment and monitoring plan for diabetes

SUNDAY

ACPE #0129-0000-24-042-L01-P 0.1 CEU

ACPE #0129-0000-24-042-H01-P 0.1 CEU

New Drug Update 2024: CV, Respiratory, GI, ID, Renal

Karen Kier, PhD, M.Sc., R.Ph.

At the completion of this activity, the participant will be able to:

1. review the pharmacology and therapeutics of selected prescription medications released to the market within the past year;
2. state the indications and clinical applications of the medications presented, and how they compare to current therapies;
3. list the most common adverse effects, toxicities, and significant drug-drug and drug-food interactions reported; and
4. explain important patient/caregiver counseling information for these medications.

ACPE #0129-0000-24-043-L04-P 0.1 CEU

ACPE #0129-0000-24-043-H04-P 0.1 CEU

What's Happening in 340B Litigation & Legislation

R. Logan Yoho, PharmD, R.Ph., BCACP, 340B ACE

At the completion of this activity, the participant will be able to:

1. review recent court decisions and cases waiting for decisions; and
2. review state legislation & federal affecting 340B covered entities and contract pharmacies.

ACPE #0129-0000-24-044-L01-P 0.1 CEU

ACPE #0129-0000-24-044-H01-P 0.1 CEU

New Drug Update 2024: CNS, Behavioral Health, Musculoskeletal, Immunology, Oncology, Ocular

Karen Kier, PhD, M.Sc., R.Ph.

At the completion of this activity, the participant will be able to:

1. review the pharmacology and therapeutics of selected prescription medications released to the market within the past year;
2. state the indications and clinical applications of the medications presented, and how they compare to current therapies;
3. list the most common adverse effects, toxicities, and significant drug-drug and drug-food interactions reported; and
4. explain important patient/caregiver counseling information for these medications.

ACPE #0129-0000-24-045-L01-P 0.1 CEU

ACPE #0129-0000-24-045-H01-P 0.1 CEU

The Salty Side of Supplements - Optimizing Supplement Selection

Emlah Tubuo, PharmD, MS

At the completion of this activity, the participant will be able to:

1. define commonly used terms to describe supplements;
2. compare commonly recommended supplements and their different formulations; and
3. outline a framework for advising patients on supplement recommendations.

ACPE #0129-0000-24-046-L01-P 0.1 CEU

ACPE #0129-0000-24-046-H01-P 0.1 CEU

A Breath of Fresh Air: 2023 COPD GOLD Report Updates

Taylor Craigo, PharmD

At the completion of this activity, the participant will be able to:

1. review COPD epidemiology, pathophysiology, diagnosis, and management;
2. explain specific updates from the 2023 GOLD Report; and
3. describe a pharmacist-led pulmonary service.

ACPE #0129-0000-24-047-L01-P 0.1 CEU

ACPE #0129-0000-24-047-H01-P 0.1 CEU

Biosimilar is a Four Letter Word—Making Sense of the Suffix

Meghan Fox, PharmD; Sarah Lorenzen, PharmD, BCACP, CSP; Dana Ortiz, PharmD, BCMTMS; Amanda Porter, PharmD, BCACP

At the completion of this activity, the participant will be able to:

- define what a biological product is, describe the difference between a generic and a biosimilar drug product, and explain the different regulatory approval pathways for reference products and biosimilars;
- identify selected biosimilars, their associated nomenclatures, and the disease states for which they are indicated;
- summarize patient assistance and copay card options for biosimilars; and
- describe managed care implications of biosimilar availability and the potential impact of such availability on patient care.